Pharmaceutical Manufacturing Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pharmaceutical Manufacturing Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pharmaceutical Manufacturing Market

5.1. Covid-19: Pharmaceutical Manufacturing Industry Impact
5.2. Pharmaceutical Manufacturing Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pharmaceutical Manufacturing Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pharmaceutical Manufacturing Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Pharmaceutical Manufacturing Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing prevalence of chronic ailments
6.1.1.2. Growing geriatric population
6.1.2. Market Restraints
6.1.2.1. Stringent Regulations
6.1.3. Market Opportunities
6.1.3.1. Increasing prevalence of chronic ailments
6.1.3.2. Growing geriatric population

Chapter 7. Global Pharmaceutical Manufacturing Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pharmaceutical Manufacturing Market Revenue by Market Players
7.1.1.2. Pharmaceutical Manufacturing Market Revenue Market Share by Market Players
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Development Type Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pharmaceutical Manufacturing Market, By Drug Development Type

8.1. Pharmaceutical Manufacturing Market, by Drug Development Type, 2024-2034
8.1.1. In-house
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Outsource
8.1.2.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Pharmaceutical Manufacturing Market, By Route of Administration

9.1. Pharmaceutical Manufacturing Market, by Route of Administration, 2024-2034
9.1.1. Topical
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Oral
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Inhalations
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Parenteral
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Pharmaceutical Manufacturing Market, By Formulation

10.1. Pharmaceutical Manufacturing Market, by Formulation, 2024-2034
10.1.1. Injectable
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Tablets
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Suspensions
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Capsules
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Sprays
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Pharmaceutical Manufacturing Market, By Therapy

11.1. Pharmaceutical Manufacturing Market, by Therapy, 2024-2034
11.1.1. Diabetes
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Respiratory Diseases
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Cancer
11.1.4.1. Market Revenue and Forecast (2021-2034)
11.1.5. Pain
11.1.5.1. Market Revenue and Forecast (2021-2034)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2021-2034)

Chapter 12. Global Pharmaceutical Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue Forecast by Drug Development Type(2021-2034)
12.1.2. Market Revenue Forecast by Route of Administration(2021-2034)
12.1.3. Market Revenue Forecast by Formulation (2021-2034)
12.1.4. Market Revenue Forecast by Therapy (2021-2034)
12.1.5. U.S
12.1.5.1. Market Revenue Forecast (2021-2034)
12.1.6. Canada
12.1.6.1. Market Revenue Forecast (2021-2034)
12.2. Europe
12.2.1. Market Revenue Forecast by Drug Development Type (2021-2034)
12.2.2. Market Revenue Forecast by Route of Administration (2021-2034)
12.2.3. Market Revenue Forecast by Formulation (2021-2034)
12.2.4. Market Revenue Forecast by Therapy (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue Forecast (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue Forecast (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue Forecast (2021-2034)
12.2.8. Rest of EU
12.2.8.1. Market Revenue Forecast (2021-2034)
12.3. Asia Pacific (APAC)
12.3.1. Market Revenue Forecast by Drug Development Type (2021-2034)
12.3.2. Market Revenue Forecast by Route of Administration (2021-2034)
12.3.3. Market Revenue Forecast by Formulation (2021-2034)
12.3.4. Market Revenue Forecast by Therapy (2021-2034)
12.3.5. China
12.3.5.1. Market Revenue Forecast (2021-2034)
12.3.6. India
12.3.6.1. Market Revenue Forecast (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue Forecast (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue Forecast (2021-2034)
12.4. LATAM
12.4.1. Market Revenue Forecast by Drug Development Type (2021-2034)
12.4.2. Market Revenue Forecast by Route of Administration (2021-2034)
12.4.3. Market Revenue Forecast by Formulation (2021-2034)
12.4.4. Market Revenue Forecast by Therapy (2021-2034)
12.4.5. Brazil
12.4.5.1. Market Revenue Forecast (2021-2034)
12.4.6. Rest of LATAM
12.4.6.1. Market Revenue Forecast (2021-2034)
12.5. Middle East and Africa (MEA)
12.5.1. Market Revenue Forecast by Drug Development Type (2021-2034)
12.5.2. Market Revenue Forecast by Route of Administration (2021-2034)
12.5.3. Market Revenue Forecast by Formulation (2021-2034)
12.5.4. Market Revenue Forecast by Therapy (2021-2034)
12.5.5. GCC
12.5.5.1. Market Revenue Forecast (2021-2034)
12.5.6. North Africa
12.5.6.1. Market Revenue Forecast (2021-2034)
12.5.7. South Africa
12.5.7.1. Market Revenue Forecast (2021-2034)
12.5.8. Rest of MEA
12.5.8.1. Market Revenue Forecast (2021-2034)

Chapter 13. Company Profiles

13.1. GlaxoSmithKline plc
13.1.1. Company Overview, Business Information, Regional Presence
13.1.2. Product Portfolio Analysis
13.1.2.1. Product Details, Specification, Formulation
13.1.3. Revenue, Price, and Gross Margin
13.1.4. Recent Developments and Strategies
13.2. Merck & Co., Inc.
13.2.1. Company Overview, Business Information, Regional Presence
13.2.2. Product Portfolio Analysis
13.2.2.1. Product Details, Specification, Formulation
13.2.3. Revenue, Price, and Gross Margin
13.2.4. Recent Developments and Strategies
13.3. Eli Lilly and Company
13.3.1. Company Overview, Business Information, Regional Presence
13.3.2. Product Portfolio Analysis
13.3.2.1. Product Details, Specification, Formulation
13.3.3. Revenue, Price, and Gross Margin
13.3.4. Recent Developments and Strategies
13.4. Johnson & Johnson
13.4.1. Company Overview, Business Information, Regional Presence
13.4.2. Product Portfolio Analysis
13.4.2.1. Product Details, Specification, Formulation
13.4.3. Revenue, Price, and Gross Margin
13.4.4. Recent Developments and Strategies
13.5. F. Hoffmann-La Roche Ltd.
13.5.1. Company Overview, Business Information, Regional Presence
13.5.2. Product Portfolio Analysis
13.5.2.1. Product Details, Specification, Formulation
13.5.3. Revenue, Price, and Gross Margin
13.5.4. Recent Developments and Strategies
13.6. Lonza
13.6.1. Company Overview, Business Information, Regional Presence
13.6.2. Product Portfolio Analysis
13.6.2.1. Product Details, Specification, Formulation
13.6.3. Revenue, Price, and Gross Margin
13.6.4. Recent Developments and Strategies
13.7. Pfizer, Inc.
13.7.1. Company Overview, Business Information, Regional Presence
13.7.2. Product Portfolio Analysis
13.7.2.1. Product Details, Specification, Formulation
13.7.3. Revenue, Price, and Gross Margin
13.7.4. Recent Developments and Strategies
13.8. Sanofi SA
13.8.1. Company Overview, Business Information, Regional Presence
13.8.2. Product Portfolio Analysis
13.8.2.1. Product Details, Specification, Formulation
13.8.3. Revenue, Price, and Gross Margin
13.8.4. Recent Developments and Strategies
13.9. Novartis AG
13.9.1. Company Overview, Business Information, Regional Presence
13.9.2. Product Portfolio Analysis
13.9.2.1. Product Details, Specification, Formulation
13.9.3. Revenue, Price, and Gross Margin
13.9.4. Recent Developments and Strategies
13.10. AstraZeneca
13.10.1. Company Overview, Business Information, Regional Presence
13.10.2. Product Portfolio Analysis
13.10.2.1. Product Details, Specification, Formulation
13.10.3. Revenue, Price, and Gross Margin
13.10.4. Recent Developments and Strategies

Chapter 14. Appendix

14.1. About Us
14.2. Glossary of Terms